Reduction of therapeutic efficacy by a second cycle of PEG-IL-2.
Steerenberg
P A
PA
Laboratory of Pathology, National Institute of Public Health and Environmental Protection, Bilthoven, The Netherlands.
Balemans
L T
LT
Kremer
B H
BH
Koppenhagen
F J
FJ
De Mulder
P H
PH
Den Otter
W
W
D000818:Animals; D000917:Antibody Formation / Q000187:drug effects; D006528:Carcinoma, Hepatocellular / Q000097:blood / Q000276:immunology / Q000628:therapy*; D005260:Female; D006168:Guinea Pigs; D007115:Immunization Schedule; D007166:Immunosuppressive Agents / Q000097:blood / Q000494:pharmacology; D007376:Interleukin-2 / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors / Q000097:blood / Q000276:immunology* / Q000627:therapeutic use; D008114:Liver Neoplasms, Experimental / Q000097:blood / Q000276:immunology / Q000628:therapy*; D011092:Polyethylene Glycols
D007166:Immunosuppressive Agents; D007376:Interleukin-2; C067245:interleukin-2, polyethylene glycol-modified; D011092:Polyethylene Glycols